Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 3
Submit an article Journal homepage
218
Views
76
CrossRef citations to date
0
Altmetric
Reviews

Developments in the treatment of visceral leishmaniasis

Margriet Leontine den Boer 23A Oval Road, NW1 7EA London, UK +44 7804952456; [email protected]
, MPH PharmD,
Jorge Alvar Medical Officer, Leishmaniasis Control, Neglected Tropical Diseases (HTM/NTD/IDM), World Health Organization, 20 Avenue Appia CH-1211 Geneva 27, Switzerland
, MD,
Robert N Davidson Northwick Park Hospital, Lister Unit, Department Infection & Tropical Medicine, Harrow, Middlesex HA1 3UJ, UK
, MD FRCP DTM&H,
Koert Ritmeijer Health Adviser/Kala-azar Adviser, Médecins Sans Frontières, Plantage Middenlaan 14, P.O.Box 10014, 1001 EA Amsterdam, The Netherlands
, PH &
Manica Balasegaram Senior Project Manager, Drugs for Neglected Diseases initiative (DNDi), 15 Chemin Louis-Dunant, 1202 Geneva, Switzerland
, MPH MD
Pages 395-410 | Published online: 27 Aug 2009

Bibliography

  • Ritmeijer K, Davidson RN. Royal society of tropical medicine and hygiene joint meeting with medecins sans frontieres at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Medecins sans frontieres interventions against kala-azar in the Sudan, 1989-2003. Trans R Soc Trop Med Hyg 2003;97(6):609-13
  • Zijlstra EE, el-Hassan AM. Leishmaniasis in Sudan. Post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 2001;95(Suppl 1):S59-76
  • Thakur CP. Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 1984;78(3):391-8
  • Addy M, Nandy A. Ten years of kala-azar in west Bengal, part I. Did post-kala-azar dermal leishmaniasis initiate the outbreak in 24-Parganas? Bull World Health Organ 1992;70(3):341-6
  • Control of the leishmaniases. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1990;793:1-158
  • Desjeux P. Human leishmaniases: epidemiology and public health aspects. World Health Stat Q 1992;45(2-3):267-75
  • Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004;27(5):305-18
  • Hotez PJ, Remme JH, Buss P, et al. Combating tropical infectious diseases: report of the disease control priorities in developing countries project. Clin Infect Dis 2004;38(6):871-8
  • Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2008;2(10):e313
  • Singh SP, Reddy DC, Rai M, Sundar S. Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health 2006;11(6):899-905
  • Barnett PG, Singh SP, Bern C, et al. Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg 2005;73(4):720-5
  • Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 1996;25(4):862-71
  • Collin SM, Coleman PG, Ritmeijer K, Davidson RN. Unseen kala-azar deaths in south Sudan (1999-2002). Trop Med Int Health 2006;11(4):509-12
  • Alvar J, Yactayo S, Bern C. Leishmaniasis and poverty. Trends Parasitol 2006;22(12):552-7
  • Cerf BJ, Jones TC, Badaro R, et al. Malnutrition as a risk factor for severe visceral leishmaniasis. J Infect Dis 1987;156(6):1030-3
  • Seaman J, Mercer AJ, Sondorp HE, Herwaldt BL. Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources. Ann Intern Med 1996;124(7):664-72
  • Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008;21(2):334-59
  • Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006;43(3):357-64
  • Ritmeijer K, Veeken H, Melaku Y, et al. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans R Soc Trop Med Hyg 2001;95(6):668-72
  • Berenguer J, Cosin J, Miralles P, et al. Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy. AIDS 2000;14(18):2946-8
  • Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol 1996;14(5):417-23
  • Molina R, Lohse JM, Pulido F, et al. Infection of sand flies by humans coinfected with Leishmania infantum and human immunodeficiency virus. Am J Trop Med Hyg 1999;60(1):51-3
  • ter Horst R, Collin SM, Ritmeijer K, et al. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008;46(11):1702-9
  • Torreele E. No drug in an age of plenty: urging governments to redress the balance. ISR 2006;31(1):7
  • Balasegaram M, Balasegaram S, Malvy D, Millet P. Neglected diseases in the news: a content analysis of recent international media coverage focussing on leishmaniasis and trypanosomiasis. PLoS Negl Trop Dis 2008;2(5):e234
  • Hunt P. Neglected diseases, a human rights analysis, 2007 social, economic and behavioural research. A WHO TDR publication. Social, economic and behavioural research 2007;Special topics (6)
  • Available from: http://www.sanger.ac.uk/Projects/Protozoa [Cited 22 June 2009]
  • Mondal D, Singh SP, Kumar N, et al. Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 2009;3(1):e355
  • Hotez PJ, Molyneux DH, Fenwick A, et al. A global fund to fight neglected tropical diseases: is the g8 hokkaido toyako 2008 summit ready? PLoS Negl Trop Dis 2008;2(3):e220
  • Trouiller P, Olliaro P, Torreele E, et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002;359(9324):2188-94
  • Davidson RN, Croft SL, Scott A, et al. Liposomal amphotericin B in drug-resistant visceral leishmaniasis. Lancet 1991;337(8749):1061-2
  • Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347(22):1739-46
  • Davidson RN, den Boer M, Ritmeijer K. Paromomycin. Trans R Soc Trop Med Hyg 2009;103(7):653-60
  • Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for Visceral leishmaniasis in India. N Engl J Med 2007;356(25):2571-81
  • DNDi and WHO joint statement to G8. Neglected tropical diseases continue to affect more than 1 billion people all over the world. Available from: http://www.dndina.org/G8Statement.html [Cited 22 June 2009]
  • Gerstl S, Amsalu R, Ritmeijer K. Accessibility of diagnostic and treatment centres for visceral leishmaniasis in Gedaref state, northern Sudan. Trop Med Int Health 2006;11(2):167-75
  • Bern C, Adler-Moore J, Berenguer J, et al. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis 2006;43(7):917-24
  • Meheus FOP, Olliaro P, Rijal S, et al. Preliminary cost-effectiveness analysis of combination therapies to combat parasite resistance to antileishmanial drugs in the Indian subcontinent. WorldLeish4; Lucknow; 2008
  • Melaku Y, Collin SM, Keus K, et al. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007;77(1):89-94
  • Seaman J, Pryce D, Sondorp HE, et al. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993;168(3):715-20
  • Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 2001;6(11):849-54
  • Goodwin LG. Pentostam (sodium stibogluconate); a 50-year personal reminiscence. Trans R Soc Trop Med Hyg 1995;89(3):339-41
  • Moore E, O'Flaherty D, Heuvelmans H, et al. Comparison of generic and proprietary sodium stibogluconate for the treatment of visceral leishmaniasis in Kenya. Bull World Health Organ 2001;79(5):388-93
  • Veeken H, Ritmeijer K, Seaman J, Davidson R. A randomized comparison of branded sodium stibogluconate and generic sodium stibogluconate for the treatment of visceral leishmaniasis under field conditions in Sudan. Trop Med Int Health 2000;5(5):312-7
  • Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg 1992;46(3):296-306
  • Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990;84(2):221-5
  • Thakur CP, Olliaro P, Gothoskar S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992;86(6):615-6
  • el-On J, Sulitzeanu A, Schnur LF. Leishmania major: resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment. Ann Trop Med Parasitol 1991;85(3):323-8
  • Fong D, Chan MM, Rodriguez R, et al. Paromomycin resistance in Leishmania tropica: lack of correlation with mutation in the small subunit ribosomal RNA gene. Am J Trop Med Hyg 1994;51(6):758-66
  • Maarouf M, Adeline MT, Solignac M, et al. Development and characterization of paromomycin-resistant Leishmania donovani promastigotes. Parasite 1998;5(2):167-73
  • Teklemariam S, Hiwot AG, Frommel D, et al. Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 1994;88(3):334-9
  • Sundar S, Agrawal G, Rai M, et al. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001;323(7310):419-22
  • Mueller M, Ritmeijer K, Balasegaram M, et al. Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. Trans R Soc Trop Med Hyg 2007;101(1):19-24
  • Collin S, Davidson R, Ritmeijer K, et al. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 2004;38(5):612-9
  • Seaman J, Boer C, Wilkinson R, et al. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions. Clin Infect Dis 1995;21(1):188-93
  • Ritmeijer K, Ter Horst RCS, Davidson RN. Poor effectiveness of liposomal amphotericin-B (AmBisome) in HIV co-infected visceral leishmaniasia patients in Ethiopia. WorldLeish4; Lucknow; 2008
  • Lima N. Experience of médecins sans frontières after 1 year of using liposomal amphotericin B (AmBisome) treatment for Indian visceral leishmaniasis under routine programme conditions in Bihar, India. Worldleish4; Lucknow; 2008
  • Sundar S, Chakravarty J, Agarwal D, et al. Safety of a pre-formulated amphotericin B lipid emulsion for the treatment of Indian kala-azar. Trop Med Int Health 2008;13(9):1208-12
  • Bekersky I, Fielding RM, Dressler DE, et al. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents Chemother 2002;46(3):828-33
  • Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007;196(4):591-8
  • Dorlo TP, van Thiel PP, Huitema AD, et al. Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients. Antimicrob Agents Chemother 2008;52(8):2855-60
  • Seifert K, Perez-Victoria FJ, Stettler M, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents 2007;30(3):229-35
  • Olliaro PL, Guerin PJ, Gerstl S, et al. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005;5(12):763-74
  • Arasteh KN, Voehringer HF, Stratmann MM, et al. Pharmacokinetics and adverse reactions of various dosage regimens of intravenous pentamidine in the treatment of HIV-associated Pneumocystis carinii pneumonia. A nonrandomised open pilot study. Drug Invest 1993;6(4):11
  • Salamone FR, Cunha BA. Update on pentamidine for the treatment of Pneumocystis carinii pneumonia. Clin Pharm 1988;7(7):501-10
  • Ena J, Amador C, Pasquau F, et al. Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clin Infect Dis 1994;18(6):901-4
  • Laguna F, Adrados M, Alvar J, et al. Visceral leishmaniasis in patients infected with the human immunodeficiency virus. Eur J Clin Microbiol Infect Dis 1997;16(12):898-903
  • Perez-Molina JA, Lopez-Velez R, Montilla P, Guerrero A. Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients. AIDS 1996;10(2):237-8
  • Seifert K, Croft SL. In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 2006;50(1):73-9
  • Sundar S, Rai M, Chakravarty J, et al. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin Infect Dis 2008;47(8):1000-6
  • Thakur CP, Kanyok TP, Pandey AK, et al. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000;94(4):429-31
  • Croft SL, Coombs GH. Leishmaniasis–current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 2003;19(11):502-8
  • Olliaro P, Lazdins J, Guhl F. Developments in the treatment of leishmaniasis and trypanosomiasis. Expert Opin Emerg Drugs 2002;7(1):61-7
  • Yardley V, Khan AA, Martin MB, et al. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother 2002;46(3):929-31
  • Croft SL, Barrett MP, Urbina JA. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 2005;21(11):508-12
  • Chappuis F, Rijal S, Soto A, et al. A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 2006;333(7571):723
  • Available from: http://www.who.int/tdr/diseases/leish/press_release.htm [Cited 23 June 2009]
  • Lockwood DN. Leprosy elimination-a virtual phenomenon or a reality? BMJ 2002;324(7352):1516-8
  • Olliaro P, Sundar S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health 2009;14(1):88-92
  • Maltezou HC. Visceral leishmaniasis: advances in treatment. Recent Pat Antiinfect Drug Discov 2008;3(3):192-8
  • Palit P, Ali N. Oral therapy with sertraline, a selective serotonin reuptake inhibitor, shows activity against Leishmania donovani. J Antimicrob Chemother 2008;61(5):1120-4
  • Miguel DC, Zauli-Nascimento RC, Yokoyama-Yasunaka JK, et al. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections. J Antimicrob Chemother 2009;63(2):365-8
  • de Oliveira-Silva F, de Morais-Teixeira E, Rabello A. Antileishmanial activity of azithromycin against Leishmania (Leishmania) amazonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. Am J Trop Med Hyg 2008;78(5):745-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.